Liquidia Technologies, Inc.
Clinical trials sponsored by Liquidia Technologies, Inc., explained in plain language.
Biopharmaceutical company developing inhaled therapies for pulmonary diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can an inhaled powder calm the painful Cold-Finger attacks of scleroderma? Results expected Feb 2027 (estimated)
- Can an inhaled therapy replace a daily pill for PAH? Results expected May 2027 (estimated)
- New inhaled powder for lung blood pressure condition tested in 80 patients Results expected Jul 2027 (estimated)
-
Can an inhaled therapy replace a daily pill for PAH?
Disease control Not yet recruitingThis trial tests whether adults with pulmonary arterial hypertension (PAH) can safely switch from selexipag, a pill taken by mouth, to LIQ861, an inhaled form of treprostinil. Participants stop selexipag on day one and start taking LIQ861 four times a day using a handheld inhaler…
Phase 4 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can an inhaled powder calm the painful Cold-Finger attacks of scleroderma?
Symptom relief Not yet recruitingThis study tests an inhaled powder called LIQ861 (treprostinil) in adults with scleroderma who have frequent, painful Raynaud's attacks—episodes where fingers or toes turn color and become numb or tingly. About 75 participants will be randomly assigned to receive either a dose th…
Phase 2 • Sponsor: Liquidia Technologies, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC